Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: An active microtubule inhibitor

Cancer Research

Volumn 71, Issue 1, 2011, Pages 216-224

  Li, Chien Ming ^a,b   Wang, Zhao ^b   Lu, Yan ^b   Ahn, Sunjoo ^a,b   Narayanan, Ramesh ^b   Kearbey, Jeffrey D ^b   Parke, Deanna N ^b   Li, Wei ^b   Miller, Duane D ^b   Dalton, James T ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; THIAZOLE DERIVATIVE; TUBULIN; VINBLASTINE;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MELANOMA; MICROTUBULE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN POLYMERIZATION; RAT;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MELANOMA; MICE; MICE, INBRED ICR; MICROTUBULES; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES; TRANSPLANTATION, HETEROLOGOUS;

EID: 78651389459     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1725     Document Type: Article

References (23)

1. Hadfield JA, Ducki S, Hirst N, McGown AT. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 2003;5:309-325.
2. Honore S, Pasquier E, Braguer D. Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci 2005;62:3039-56.
3. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18: 259-96.
4. Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007;7:730-42.
5. Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009;8:2086-95.
6. Heinz DW, Schubert WD, Hofle G. Much anticipated-the bioactive conformation of epothilone and its binding to tubulin. Angew Chem Int Ed Engl 2005;44:1298-1301.
7. Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008;63:157-66.
8. Polgar O, Bates SE. ABC transporters in the balance: is there a role in multidrug resistance? Biochem Soc Trans 2005;33:241-45.
9. Michels J, Ellard SL, Le L, Kollmannsberger C, Murray N, Tomlinson Guns ES, et al. A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Ann Oncol 2010;21:305-11.
10. Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, KromplewskiM, et al.Aphase I study ofABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 2008;14:1111-15.
11. Lu Y, Li CM, Wang Z, Ross CR II, Chen J, Dalton JT, et al. Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J Med Chem 2009;52:1701-11.
12. Alley MC, Hollingshead MG, Dykes DJ, Waud WR. Human tumor xenograft models in NCI drug development. In: Teicher BA and Andrews PA, editors. Anticancer Drug Development Guide. Totowa, NJ: Humana Press; 2004. p. 125-52.
13. Li CM, Lu Y, Ahn S, Narayanan R, Miller DD, Dalton JT, et al. Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin. J Mass Spectrom 2010;45:1160-6
14. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-95.
15. Jordan MA. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
16. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 2001;98:11737-42.
17. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999;17:1786-93.
18. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997;49:403-49.
19. Fukuda DS, Mabe JA, Brannon DR. Production of substituted Ltryptophans by fermentation. Appl Microbiol 1971;21:841-3.
20. Windebank AJ. Chemotherapeutic neuropathy. Curr Opin Neurol 1999;12:565-71.
21. Li CM, Lu Y, Narayanan R, Miller DD, Dalton JT, et al. Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles. Drug Metab Dispos 2010;38:2032-9.
22. Nakai R, Iida S, Takahashi T, Tsujita T, Okamoto S, Takada C, et al. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res 2009;69:3901-9.
23. Bacher G, Nickel B, Emig P, Vanhoefer U, Seeber S, Shandra A, et al. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 2001;61: 392-99.